Compare iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares S&P GSCI Commodity-Indexed Trust ETF vs Smith & Nephew plc — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $30.87, while Smith & Nephew plc trades at $31.41 (market cap $12.81B). The key difference: Smith & Nephew plc pays a 2.54% dividend while iShares S&P GSCI Commodity-Indexed Trust ETF pays none, and iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| GSG | SNN | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $34.77 | $38.70 |
52-Week Low | $22.06 | $28.73 |
Market Cap | — | $12.81B |
Enterprise Value | — | $15.58B |
Dividend Yield | — | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSG, the iShares S&P GSCI Commodity-Indexed Trust ETF, trades at $30.85, down 0.48% on the day. Technical indicators show a bullish trend with moving averages strongly positive, though oscillators are neutral and short-term RSI signals suggest overbought conditions. Recent financial media highlights a thematic focus on commodities as a key market driver, with notable investors increasing exposure to the sector.
The outlook for GSG is tied to commodity price trends and broader economic developments. Investment opportunity lies in exposure to a constrained supply environment and inflation hedging. Primary risks include commodity price volatility, global economic slowdowns reducing demand, and the ETF's structure leading to tracking error or contango in futures markets.
Smith & Nephew (SNN) trades at $31.41, up 5.28% today, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $5.8B in 2024 to $6.2B projected for 2025 and net income margin expanding to 10.14%. Recent product launches in robotics and wound care, plus a $500M share buyback, highlight strategic execution. Analyst consensus is mixed with 27% buy ratings but 68% hold, reflecting cautious optimism amid earnings volatility where two of the last four quarters missed expectations.
Outlook: SNN's recovery trajectory and product innovation support long-term growth, but investor patience is needed due to earnings inconsistency and moderate debt levels. Key risks include competitive pressures in medtech and execution on guidance. The stock presents a value opportunity if operational improvements continue, trading at reasonable valuations (P/E 21.5, P/S 2.18) versus sector peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
